When do Victoza and Saxenda patents expire in Japan?
The provided information does not include the specific Japan patent expiry dates for Victoza (liraglutide) or Saxenda (liraglutide). Without the relevant patent/publication numbers or a source that lists Japan’s patent expiry timelines for these products, exact expiry dates can’t be confirmed from the available material.
Do Victoza and Saxenda share the same underlying molecule, and does that affect Japan patent expiry?
Both Victoza and Saxenda use the same active ingredient (liraglutide), but they are marketed for different indications (diabetes for Victoza; weight management for Saxenda). In practice, Japan’s effective “expiry” timing can differ by indication because the relevant patent set may include different claims tied to specific uses, formulations, dosing, or manufacturing—so you may see different effective exclusivity end dates even if the molecule is the same.
What usually determines “patent expiry” timing for branded drugs in Japan?
Japan’s end of exclusivity for a brand can hinge on more than one factor, such as the final expiry of key patents covering the product and whether any additional protections apply to specific claims. For a precise answer, you typically need the specific Japanese patents (or patent families) asserted for Victoza and Saxenda, then map their scheduled expiration dates.
If you need the exact Japan expiry dates, what details should you provide?
If you share either (1) the Japanese patent/publication numbers for the Victoza and Saxenda patent families you care about, or (2) links to the listing/source you’re using, I can translate that into the expected expiry timeline in Japan and explain how it relates to each brand and indication.
Alternative: how to quickly verify Japan expiry yourself
To get exact dates, the most direct approach is to search Japan’s patent records by the relevant liraglutide patent families for each brand, then check the scheduled expiration dates of the surviving claims in Japan.
Sources
No sources were provided in the prompt to cite for Japan patent expiry dates of Victoza and Saxenda.